BACKGROUND: To further investigate the relationship between ADH2 Arg47His variation and hepatocellular carcinoma (HCC) susceptibility through a meta-analysis. METHODS: The related articles were searched in PubMed, Embase and CNKI databases. And finally 518 cases and 607 controls were included in our meta-analysis Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the relationship between ADH2 Arg47His variation and HCC risk. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. RESULTS: Quantitative synthesis demonstrated that no significant association was found between ADH2 Arg47His variation and HCC susceptibility (His/His vs. Arg/Arg: OR=0.99, 95% CI=0.79-1.25; His/His + Arg/His vs. Arg/Arg: OR=1.01, 95% CI=0.86-1.20; His/His vs. Arg/Arg + Arg/His: OR=0.90, 95% CI=0.74-1.11; His vs. Arg: OR=0.98, 95% CI=0.86-1.11; Arg/His vs. Arg/Arg: OR=1.05, 95% CI=0.82-1.34). CONCLUSION: Our analysis showed that ADH2 Arg47His vvariation may not be associated with HCC susceptibility.
BACKGROUND: To further investigate the relationship between ADH2 Arg47His variation and hepatocellular carcinoma (HCC) susceptibility through a meta-analysis. METHODS: The related articles were searched in PubMed, Embase and CNKI databases. And finally 518 cases and 607 controls were included in our meta-analysis Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the relationship between ADH2 Arg47His variation and HCC risk. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. RESULTS: Quantitative synthesis demonstrated that no significant association was found between ADH2 Arg47His variation and HCC susceptibility (His/His vs. Arg/Arg: OR=0.99, 95% CI=0.79-1.25; His/His + Arg/His vs. Arg/Arg: OR=1.01, 95% CI=0.86-1.20; His/His vs. Arg/Arg + Arg/His: OR=0.90, 95% CI=0.74-1.11; His vs. Arg: OR=0.98, 95% CI=0.86-1.11; Arg/His vs. Arg/Arg: OR=1.05, 95% CI=0.82-1.34). CONCLUSION: Our analysis showed that ADH2 Arg47His vvariation may not be associated with HCC susceptibility.
Authors: Eric J Duell; Núria Sala; Noémie Travier; Xavier Muñoz; Marie Christine Boutron-Ruault; Françoise Clavel-Chapelon; Aurelio Barricarte; Larraitz Arriola; Carmen Navarro; Emilio Sánchez-Cantalejo; J Ramón Quirós; Vittorio Krogh; Paolo Vineis; Amalia Mattiello; Rosario Tumino; Kay-Tee Khaw; Nicholas Wareham; Naomi E Allen; Petra H Peeters; Mattijs E Numans; H B Bueno-de-Mesquita; M G H van Oijen; Christina Bamia; Vassiliki Benetou; Dimitrios Trichopoulos; Federico Canzian; Rudolf Kaaks; Heiner Boeing; Manuela M Bergmann; Eiliv Lund; Roy Ehrnström; Dorthe Johansen; Göran Hallmans; Roger Stenling; Anne Tjønneland; Kim Overvad; Jane Nautrup Ostergaard; Pietro Ferrari; Veronika Fedirko; Mazda Jenab; Gabriella Nesi; Elio Riboli; Carlos A González Journal: Carcinogenesis Date: 2011-12-05 Impact factor: 4.944
Authors: K Tanaka; T Hirohata; S Koga; K Sugimachi; T Kanematsu; F Ohryohji; H Nawata; H Ishibashi; Y Maeda; H Kiyokawa Journal: Cancer Res Date: 1991-06-01 Impact factor: 12.701